Canada Seeks To Disclose Drug Applicants Under Transparency Drive
Executive Summary
Health Canada is seeking feedback on five transparency proposals that include publishing the names of sponsors whose prescription drugs containing new active substances are under review, and making information on generic drug submissions public for the first time.
You may also be interested in...
New Canadian Transparency Drive To Facilitate Better Planning For Industry
Health Canada is making its decision-making process in the pre-market phase more transparent by disclosing a wider range of information on new and generic drug applications accepted for review.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.